HDAC9 and cancer: The clinical use of HDAC inhibitors was mainly tested on the treatment of cancer due to their documented antiproliferative activities involving the regulation of gene expression, cell cycle arrest, apoptosis, and anti-angiogenetic effects (157, 158).